Drug
Nbi 74788
Nbi 74788: highest development phase Phase 2, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-74788 NCT03525886 | Phase 2 | CAH - Congenital Adrenal Hyperplasia |
Latest
No recent events.
Follow Nbi 74788 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.